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Abstract
The mitochondrial permeability transition pore (mtPTP) is a Ca2+-requiring mega-channel which, 
under pathological conditions, leads to the deregulated release of Ca2+ and mitochondrial 
dysfunction, ultimately resulting in cell death. Although the mtPTP is a potential therapeutic target 
for many human pathologies, its potential as a drug target is currently unrealized. Herein we 
describe an optimization effort initiated around hit 1, 5-(3-hydroxyphenyl)-N-(3,4,5-
trimethoxyphenyl)isoxazole-3-carboxamide, which was found to possess promising inhibitory 
activity against mitochondrial swelling (EC50 < 0.39 µM) and showed no interference on the inner 
mitochondrial membrane potential (rhodamine 123 uptake EC50 > 100 µM). This enabled the 
construction of a series of picomolar mtPTP inhibitors that also potently increase the calcium 
retention capacity of the mitochondria. Finally, the therapeutic potential and in vivo efficacy of 
one of the most potent analogues, N-(3-chloro-2-methylphenyl)-5-(4-fluoro-3-
hydroxyphenyl)isoxazole-3-carboxamide (60), was validated in a biologically relevant zebrafish 
model of collagen VI congenital muscular dystrophies.
Correspondence to: Michael A. Forte, forte@ohsu.edu; Paolo Bernardi, bernardi@bio.unipd.it; Frank J. Schoenen, 
schoenen@ku.edu.
+These authors contributed equally to this work.
Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/cmdc.201500284.
HHS Public Access
Author manuscript
ChemMedChem. Author manuscript; available in PMC 2015 December 09.
Published in final edited form as:














calcium retention capacity; mitochondria; muscular dystrophy; permeability transition; zebrafish
Introduction
The vital roles of mitochondria involve ATP synthesis, redox signaling, and regulation of 
cytoplasmic and mitochondrial matrix calcium (Ca2+) levels.[1] The latter function is 
reflected by the mitochondrion’s high capacity to store Ca2+ in response to signals arising 
from elevated cytoplasmic Ca2+ concentrations.[2] The mitochondrial permeability transition 
pore (mtPTP) is a high-conductance channel of the inner mitochondrial membrane (IMM) 
sensitive to cyclosporin (Cs) A that opens transiently under normal physiological conditions, 
possibly acting as a mitochondrial Ca2+-release channel to help maintain cellular Ca2+ 
homeostasis.[3] However, under pathological conditions, the mtPTP opens persistently and 
results in fatal consequences such as IMM depolarization, deregulated release of matrix 
Ca2+, termination of oxidative phosphorylation, swelling, and eventually rupture of the outer 
mitochondrial membrane (OMM) with the release of apoptotic proteins, resulting in cell 
death.[3c, 4] Persistent opening of the mtPTP may contribute to a host of chronic and 
therapeutically challenging diseases, such as multiple sclerosis,[5] amyotrophic lateral 
sclerosis,[6] Alzheimer’s disease,[7] muscular dystrophies,[8] myocardial infarction,[9] 
stroke,[10] and diabetes.[11] A key pathophysiological hallmark in these diseases is likely 
based in mitochondrial dysfunction triggered by Ca2+ and potentiated by oxidative stress.[12]
The molecular composition of the mtPTP is still incompletely understood.[13] The previous 
long-standing belief that the mtPTP forms at the adjoining sites of the inner and outer 
membranes through association of the voltage-dependent anion channel (VDAC)[14] of the 
OMM and the adenine nucleotide translocator (ANT)[15] of the IMM has not been supported 
by rigorous genetic tests, as VDAC- and ANT-null mitochondria still display a CsA-
sensitive mtPTP.[16] Over the past decade, similar genetic analyses have discounted the 
participation of many other components of the earlier models of the mtPTP.[17] Other 
studies suggest that the mtPTP forms from dimers of the FOF1 ATP synthase (F-ATP 
synthase), the IMM nanomachine responsible for the synthesis of ATP.[18] In this context, 
the mtPTP represents a unique, Ca2+-dependent channel originating from F-ATP synthase 
that is highly favored by formation of disulfide bonds during oxidative stress.[19] How 
dimers of F-ATP synthase switch from a Mg2+-dependent catalytic system that makes or 
hydrolyses ATP into a Ca2+-dependent pore that eliminates the IMM transmembrane 
potential, which is required for ATP synthesis, remains to be established. While many 
mtPTP inhibitors have been reported (a few are shown in Figure 1), most of them are not 
selective and likely inhibit the mtPTP through indirect effects.[20] The most studied inhibitor 
of the mtPTP is CsA. CsA binds to cyclophilin (CyP) D, a matrix peptidylprolyl cis–trans 
isomerase (PPIase) and inhibits its activity. However, CyPD inhibitors only desensitize the 
mtPTP without blocking its activity, as demonstrated by the fact that the mtPTP can still 
open after elimination of the nuclear gene encoding CyPD.[21] CsA binds to and inhibits the 
action of all members of the CyP family (16 different CyP proteins are encoded by 
mammalian genomes).[22] As a result, through interaction with another member of this 
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family, CyPA, CsA also mediates inhibition of calcineurin, resulting in immunosuppression, 
which is a major side effect of therapy for mtPTP-dependent diseases.[23] Consequently, 
non-immunosuppressive CyPD inhibitors (e.g., NIM811, Debio025, and antamanide)[24] 
derived from CsA have been used as therapeutic agents in mtPTP-dependent disease 
models.[25] However, all CsA derivatives inhibit all CyPs to some extent—not just the 
mitochondrial isoform—and, like CsA, desensitize, but do not block, the mtPTP. 
Furthermore, CsA and its derivatives cannot be used to treat mtPTP-based neurological 
diseases because they do not cross the blood–brain barrier.[23, 26]
Despite the above advances, more potent and selective mtPTP inhibitors are needed for use 
as tool compounds and for possible drug discovery activities. Herein we report the results of 
a screening/chemical optimization approach that has yielded small-molecule inhibitors of 
the mtPTP that are ~1000-fold more potent than GNX-865 (which is one of the most 
relevant prior-art compounds, as reported by Fancelli et al.[27]) in the mitochondrial swelling 
assay and also exhibit high in vivo efficacy in a zebrafish model of collagen VI (ColVI) 
congenital muscular dystrophies, a biologically accurate model of a mtPTP based 
disease.[28]
Results and Discussion
Identification of small-molecule mtPTP inhibitors
As a part of the Molecular Libraries Program of the US National Institutes of Health (NIH), 
a high-throughput screen was performed within the Molecular Libraries Probe Production 
Centers Network (MLPCN) to seek new structural hits for the development of potent, small-
molecule inhibitors of mtPTP (PubChem Summary AID: 602491).[29] The NIH Molecular 
Libraries Small Molecule Repository (MLSMR) collection of 363 827 compounds was 
screened at a concentration of 10 µM in isolated mouse liver mitochondria using the mtPTP 
swelling assay. Compounds were selected as hits if they were found to inhibit mitochondrial 
swelling by at least 50% relative to controls. Using this selection criterion, 5040 compounds 
were identified, corresponding to a hit rate of 1.4% (PubChem AID: 602449). These 
compounds were subsequently tested in the mitochondrial rhodamine (Rh) 123 uptake assay 
to identify and exclude probes that interfered with maintenance of the IMM potential (thus 
preventing Ca2+ uptake) rather than inhibiting the mtPTP. Compounds exhibiting >20% 
inhibition at 10 µM in this counter-screen assay were excluded from further consideration, 
which resulted in 1097 compounds of interest. This list was condensed further to 819 
compounds based on cheminformatic identification of biologically promiscuous compounds 
(PubChem Promiscuity) and PAINS (Pan Assay Interference Compounds).[30] The 
concentration–response effect of these compounds was measured in the mitochondrial 
swelling (PubChem AID: 651561) and Rh123 uptake assays (PubChem AID: 651564) and 
yielded 248 compounds with EC50 < 20 µM in the swelling assay, and a Rh123-uptake-to-
swelling EC50 ratio of >5-fold, benchmark criteria that were established at the outset of the 
project. A final prioritization of compounds was based on lack of reactive functionalities and 
synthetic tractability, followed by validation of activity on high-quality compound samples 
from the solid physical state. A total of 27 hits, along with CsA as a positive control, were 
assayed by the calcium retention capacity (CRC) test, a good alternative to the 
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mitochondrial swelling assay used as the primary screen. Amongst all of the validated hits, 
compounds from the isoxazole chemotype exhibited activity similar to that of CsA in 
isolated mouse liver mitochondria and also increased the CRC of permeabilized mouse 
(murine embryonic fibroblasts) and human (HeLa) cells, thereby demonstrating that their 
effects were not mouse-specific. Based on biological activity and physicochemical 
properties, the isoxazole scaffold, represented by hit compound 1 (Figure 2), was selected as 
a starting point for further structure–activity relationship (SAR) studies.
Isoxazole compounds are novel structural entities that target the mtPTP
Isoxazole compounds are known for their potential use in a broad array of diseases across 
the infectious and parasitic diseases and oncology therapeutic areas, etc.[31] However, the 
potential use of isoxazole compounds to probe mtPTP-related diseases has not been 
reported. Although not directly comparable with activity against the mtPTP, 
piperazinylalkylisoxazole compounds have been reported as inhibitors of T-type Ca2+ 
channel blockers.[32] Regardless, the isoxazole compounds reported herein contain a phenyl 
ring at the 5-position of the isoxazole unit and an anilide functionality off the 3-position, and 
these features make the isoxazole compounds reported herein structurally unique to the 
above-mentioned piperazinylalkylisoxazole-containing compounds.
Isoxazole compound analogue synthesis
Generally, analogues of 1 were assembled by coupling the isoxazole-core-containing 
carboxylic acids 2 and anilines 3 using thionyl chloride and triethylamine in tetrahydrofuran 
(THF) (Scheme 1A) to afford the corresponding isoxazole amides 4 in 20–80% yield. For 
some of these isoxazole amides, the corresponding carboxylic acid partners, as well as the 
aniline coupling partners, were commercially available. For the assembly of non-isoxazole-
core-containing amides, a similar coupling strategy was used (Scheme 1B).
For the isoxazole-containing or different heterocycle-containing carboxylic acids that were 
not commercially available, a three-step procedure was required for their assembly (Scheme 
2). The acetophenone derivatives 8 were treated with dimethyl oxalate and sodium 
methoxide in diethyl ether for 24 h at room temperature to give the corresponding 1,3-
diketones[33] 9 in 60–80% yield, which are present predominantly in the enol form, 9a. At 
this point, depending on the desired heterocyclic motif, the enols 9a were treated with 
hydroxylamine hydrochloride in methanol under reflux conditions to form the isoxazole[34] 
core 10a, or, upon treatment with hydrazine hydrate in acetic acid, afforded the pyrazole 
core as a 1:1 mixture of regioisomers 10b/10b′, whereas using methylhydrazine in methanol 
under reflux conditions afforded a 1:1 mixture of regioisomers of the methylpyrazoles 
10c/10c′ in 40–90% overall yield. Subsequent saponification of the methyl esters in these 
compounds with sodium hydroxide in ethanol/THF (2:1) for 2 h at reflux provided the 
corresponding carboxylic acid intermediates 11a, 11b, 11b′, 11 c, and 11 c′ in 70–98% 
yields.
Structure–activity relationship optimization
Using CsA and GNX-865 as positive controls, SAR optimization was driven using three 
assays, namely: 1) mitochondrial swelling, which is an absorbance-based assay used to 
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assess the concentration–response activity of mtPTP inhibitors; 2) Rh123 uptake, which is a 
fluorescence-based counter-screen assay performed to identify compounds that prevent 
mitochondrial swelling by interfering with IMM potential rather than blocking or binding to 
the mtPTP; and 3) the CRC test, which measures the amount of Ca2+ accumulated and 
retained by the mitochondria before the precipitous Ca2+ release marking opening of the 
mtPTP. The ratio between the amounts of Ca2+ required to trigger pore opening in the 
presence (CRC) versus absence of test compound (CRC0), is a direct measure of the 
inhibitory effect on the mtPTP and is known as the CRC ratio (CRC/CRC0). Guided by 
these three key assays, we explored structural modifications primarily around the western 
and the eastern aryl rings and the isoxazole central core (highlighted regions in Figure 2) to 
discover efficacious inhibitors.
With respect to SAR for the western aryl ring, it became evident that introduction of the 3-
chlorophenyl moiety improved activity (Table 1, entry 14) and migration of the chlorine 
atom or its replacement around the ring (entry 15 versus 16) caused activity to decrease. 
Introducing 3,5-dichloro or 3-chloro-5-methyl substitution on the phenyl ring (entries 23 and 
30), as well as the 5-chloro-2-methyl, 5-chloro-2-cyano, 5-chloro-2-methoxy pattern on the 
phenyl ring (entries 29, 25, and 27), which all have the 3-chlorophenyl moiety intact, 
resulted in considerable enhancement in activity. Interestingly, introducing the 2,6-
dimethylphenyl moiety enhanced activity (entry 33), which might suggest a role for sterics 
in perturbing the coplanarity of the 2,6-dimethylphenyl ring and the amide bond. 
Introducing a heteroatom in the phenyl ring (entry 31) was tolerated with a modest loss of 
activity.
With respect to the eastern aryl ring, varying the position of the phenolic hydroxy group 
(Table 2, entries 38–43), bioisosteric replacement of the hydroxy group with N-
methylsulfonamide (NHSO2Me; entries 44 and 45), protection of the hydroxy group as 
methoxy (entry 37), and deletion of the hydroxy group (entry 35), resulted in diminished or 
no activity, indicating the importance of the 3-hydroxyphenyl moiety.
Having determined desirable substitution patterns on the eastern and western aryl rings, we 
explored the effect of additional substituents in the eastern aryl ring. To that end, we 
explored the effect of electron-withdrawing and electron-donating groups on the adjacent 
phenol group. Analogues containing the 3-hydroxy-4-methoxyphenyl moiety resulted in 
very-good-to-excellent activity (Table 3, entries 46–55), particularly the 5-chloro-2-
methylphenyl amalgamation (entry 46), which resulted in single-digit picomolar activity in 
the mitochondrial swelling assay and a very high CRC ratio of 10 at 1.56 µM, whereas the 3-
chloro-2-methylphenyl combination (entry 52) showed similar potency of 28 pM activity in 
the mitochondrial swelling assay and a CRC ratio of 9.6 at 1.56 µM. Furthermore, the 5-
chloro-2-methylpyridin-3-yl counterpart displayed 10 nM activity in the mitochondrial 
swelling assay and a CRC ratio of 10 (entry 54). However, complete loss of activity was 
observed with the incorporation of 3,4-dimethoxyphenyl substitution in the eastern ring, 
reiterating the importance of the 3-hydroxyphenyl moiety for activity (entries 56 and 57).
With respect to exploring the effect of electron-withdrawing groups by introducing a fluoro 
functionality adjacent to the phenolic hydroxy group, we obtained inhibitory activity 
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analogous to that observed for the methoxy series, and, in some cases, even better activity 
(entries 58–67). The 5-chloro-2-methylphenylanilino and 3-chloro-2-methylphenylanilino 
analogues demonstrated sub-nanomolar activity in the mitochondrial swelling assay and 
very high CRC ratios of 15 and 12, respectively, at 1.56 µM (entries 63 and 60). The 
chloro-2-methylpyridin-3-yl aniline analogue displayed 16 nM activity in the mitochondrial 
swelling assay along with a CRC ratio of 9 (entry 66). Similarly, insertion of a chloro 
functionality adjacent to the phenolic hydroxy group afforded analogues with good activity 
(entries 68–70).
Finally, we studied modifications to the central core of the scaffold. Replacing the isoxazole 
core with phenyl (Table 4, entry 71), 6-methylquinoline (entries 77 and 84), and 5-
oxopyrrolidine (entries 78 and 79) rings attenuated the activity. Conversely, replacement 
with 1H-pyrazole or 1-methyl-1H-pyrazole conserved activity (entries 72–74), whereas their 
regioisomers (entries 75 and 76) were inactive. More surprising was the effect of 
introducing thiophene and furan rings (entries 80, 81, and 82), as the resulting compounds 
showed activity in the Rh123 uptake assay, indicative of preventing mitochondrial swelling 
by interference with IMM potential rather than blocking or binding to the mtPTP.
Compound 60 is a key compound based on potency, selectivity, physicochemical 
properties, and efficiency indices
Overall, the SAR studies revealed a set of seven very potent analogues (Figure 3), with 46 
having the lowest mitochondrial swelling activity (EC50 = 7.6 pM) and 63 having the highest 
CRC ratio of 15 at 1.56 µM. We identified four key compound analogues based on excellent 
inhibitory activities, CRC ratios, and physicochemical properties. These four analogues 
shared very promising physicochemical properties (Table 5) and desirable values for binding 
efficiency[35] metrics, such as ligand efficiency (LE) and lipophilic ligand efficiency (LLE). 
With respect to in vitro potency and efficacy, all four analogues were comparably matched; 
however, 60 and 63 were favored in terms of slightly decreased topological polar surface 
area and the number of hydrogen bond acceptors. In addition, the measured aqueous 
solubility for compound 60 was 16 µM in PBS at pH 7.4, which was the best of the four key 
analogues. In light of its promising in vitro potency, selectivity, and physicochemical 
properties, compound 60 was prioritized for more extensive biological characterization.
Profiling of compound 60 in Eurofins LeadProfilingScreen and for in vitro drug metabolism 
and pharmacokinetic properties
Compound 60 was profiled against a panel of 68 G-protein-coupled receptors (GPCRs), ion 
channels, and transporters. At a concentration of 10µM, 79% inhibition of human 
norepinephrine transporter (NET) and 51% inhibition of adenosine A3 were observed, 
whereas inhibition of the other 66 targets in the panel was ≤ 43 %.[36] Moreover, the desired 
activity of compound 60 in the swelling assay is achieved at >1000-fold lower concentration 
than the counter-screen activity against the NET and adenosine A3 targets.
Compound 60 was submitted for in vitro drug metabolism and pharmacokinetic profiling to 
establish a baseline against which future analogues could be compared (Table 6). Compound 
60 demonstrated acceptable human plasma protein binding and very high binding for mouse 
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plasma proteins. Assessment of in vitro metabolism revealed a very good half-life in human 
plasma, whereas a poor half-life was observed in mouse plasma. Similarly, greater 
compound stability was observed in human liver microsomes, relative to the stability 
observed in mouse liver microsomes. Clearly, there is room for improvement for an 
optimized lead compound compared with compound 60.
Inhibitory effect of compound 60 on Ca2+-induced mtPTP opening
Elevated levels of matrix Ca2+ concentration and oxidative stress sensitize the mtPTP to 
open, resulting in an increased permeability of the otherwise impermeant IMM to ions and 
solutes up to ~1500 Da in size. In vitro mitochondrial volume changes can be followed 
spectrophotometrically as a decrease in absorbance at λ 540 nm. Consequently, we tested 
mtPTP opening in isolated mouse liver mitochondria, induced by a 50 µM Ca2+ load (Figure 
4A, trace a) which was abolished in the presence of compound 60 at 1.56 µM, (Figure 4A, 
trace b). A full concentration–response assessment, ranging from 18.6 pM to 1.56 µM, 
revealed a mitochondrial swelling EC50 value of 0.89 ± 1.42 nM (Figure 4B, trace a), which 
is two orders of magnitude more potent than that of CsA or GNX-865 (Table 1). Moreover, 
we confirmed that the lack of mitochondrial swelling in the presence of the inhibitors was 
due to mtPTP desensitization, and does not decrease the IMM potential (Figure 4B, trace b).
Compound 60 and CsA likely act on different biological targets
In the following assays, we used isolated mouse liver mitochondria as the test material 
because they are easily prepared and give consistent and reproducible results. Ample 
literature indicates that these mitochondria respond to pore agonists and inhibitors as human 
mitochondria respond.[3a] A suspension of mouse liver mitochondria supplemented with the 
membrane-impermeant fluorescent dye Calcium Green-5N at 0.5 µM was loaded with a train 
of 20 µM Ca2+ pulses until the threshold was reached and precipitous Ca2+ release was 
registered, marking opening of the mtPTP (e.g., Figure 4C). The presence of 1.56 µM 60 
raised the Ca2+ load required for mtPTP opening from 80 to ~960 nmol (mg protein)−1 
(Figure 4C traces a and c, respectively), which was further increased by augmenting the 
concentration of 60, eventually culminating in the compound-to-solvent CRC ratio of 15 
(Figure 4D, trace a). Based on our findings that the maximum CRC ratios of isolated mouse 
liver mitochondria treated with 60 are ~3-fold higher than those treated with CsA (Figure 
4C, compare traces c and a, and traces b and a), we suspected that our inhibitors and CsA act 
on different biological targets. To address this, we treated mitochondria with 2 µM CsA 
together with various concentrations of 60 and performed the CRC test. We found that the 
two compounds’ effects are synergistic at all tested concentrations of 60 (Figure 4C,D), 
indicating the target of diarylisoxazole-3-carboxamides is likely not CyPD.
Compound 60 inhibits human mtPTP
Given that our mtPTP inhibitors were identified and optimized using murine mitochondria, 
and that species-specific regulation of the mtPTP has been demonstrated,[18b, 37] we tested 
whether human mtPTP is also affected by 60. The inhibitory effect of 60 on human 
mitochondria was initially confirmed by the increased CRC ratios of permeabilized HeLa 
cells upon treatment with increasing concentrations of 60 (Figure 4F). Moreover, we treated 
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intact HeLa cells with 1.56 µM 60 or DMSO for 30 min and washed them to eliminate excess 
60 by centrifugation. Cells were then permeabilized with digitonin, and the CRC was 
assessed. As shown in Figure 4E, we observed that 60 is effective following treatment of 
intact human cells (compare traces a and c), indicating that it was able to permeate the 
plasma membrane and reach its mitochondrial target, thus desensitizing mtPTP activation to 
the same extent as DMSO-treated cells (trace b).
Compound 60 protects against chemical activation of mtPTP
We next investigated whether 60 is protective against known chemical activators of the 
mtPTP that result in oxidative stress and trigger pore opening. We pretreated isolated mouse 
liver mitochondria with 10 µM Ca2+, an amount insufficient to induce mtPTP opening per se 
(Figure 5 traces a), and challenged them with reagents that react with two distinct classes of 
redox-sensitive thiols and increase the mtPTP sensitivity to Ca2+: 1) PhAsO (Figure 5A) and 
diamide (Figure 5B), which react with matrix thiols;[38] and 2) Cu(OP)2 and NEM (Figure 
5C,D, respectively), which react with intermembrane space exposed thiol groups.[39] In all 
cases, the mtPTP transition, from closed to open conformation, was delayed by CsA at 1.56 
µM and was prevented by compound 60 at the same concentration, as measured by the lack of 
mitochondrial swelling (Figure 5 traces c and d, respectively). Therefore, the isoxazole 
inhibitors prevented mtPTP opening irrespective of changes in calcium flux and stimuli that 
would induce pore opening.
Compound 60 shows no effect on ATP synthesis and HeLa cell proliferation
Because it was recently suggested that the mtPTP is formed by a unique conformation of F-
ATP synthase dimers,[18, 37b] we investigated whether apart from preventing mtPTP 
formation, compound 60 also affects ATP synthesis, a potentially untoward side effect. 
Thus, we measured mitochondrial respiration both in isolated mouse liver mitochondria and 
in intact HeLa cells in the presence or absence of the inhibitor. No statistically significant 
differences in respiratory control ratios (Figure 6B), or FCCP-stimulated and oligomycin-
insensitive respiration were observed in both isolated mouse liver mitochondria (Figure 6A) 
and HeLa cells (Figure 6C), demonstrating that the diarylisoxazole-3-carboxamides do not 
affect the respiratory chain complexes or inherent function of F-ATP synthase. Indeed, 
compound 60 was not cytotoxic up to a concentration of 12.50 µM (CC50 = 39.5 ± 4.65 µM; 
Figure 6D) as confirmed by the similar number of viable HeLa cells after treatment for 24 h. 
Note that as an additional precaution, the plasma membrane multidrug resistance pump 
inhibitor CsH (which does not inhibit the PTP)[40] (Figure 6D) or verapamil[41] (data not 
shown) were added in these experiments to ensure that 60 is not extruded from the cells. 
Similar results were observed following treatment of HEK293 cells and murine embryonic 
fibroblasts with 60 (data not shown).
Compound 60 shows therapeutic potential in a validated vertebrate model of mtPTP-based 
disease
As noted above in the Introduction, activation of the mtPTP has been implicated in some of 
the most challenging human disorders. Indeed, our true appreciation of the extent of mtPTP 
activation in human diseases was only fully developed through the creation of mice lacking 
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CyPD and performing tests in murine models of these disorders. Among these are muscular 
dystrophies due to the absence of the extracellular matrix protein ColVI. ColVI is an 
essential component of myofiber extracellular matrix; mutations in ColVI result in two 
major human diseases: Ullrich congenital muscular dystrophy (UCMD) and Bethlem 
myopathy (BM).[42] Mouse models of UCMD have been created through knock-out of the 
murine Col6a1 gene, but, in contrast to UCMD patients, homozygous recessive animals 
exhibit very mild clinical myopathy.[43] However, in both humans and mice, assessment of 
mitochondrial characteristics amply documented that inappropriate mtPTP activity plays a 
key role in disease pathogenesis.[43b, 44] Consistent with this idea, modification of the 
mtPTP, either pharmacologically in humans and in mice (with CsA and non-
immunosuppressive derivatives such as Debio025 or NIM811),[8b, 25b, 28b, 45] or elimination 
of the mouse gene encoding CyPD,[46] was found to improve mitochondrial changes and to 
decrease myofiber cell death. A more robust model of UCMD has been generated in 
zebrafish by the injection of antisense morpholino oligonucleotides directed to the exon 9 
splicing region of the orthologous ColVIa gene.[28] This treatment results in an in-frame 
deletion paralleling common mutations in UCMD.[47] Severe myopathy, motor deficits, and 
dramatic ultrastructural defects are present in morpholino-injected animals that successfully 
recapitulate the clinical severity of human UCMD.[28] Furthermore, treatment with 
NIM811[28b] reversed many of these defects. Consequently, we used the zebrafish ColVI 
myopathic model as a convenient, powerful, and easily assayed in vivo system to validate 
the therapeutic potential of the most potent diarylisoxazole-3-carboxamide mtPTP inhibitors 
outlined here.
Zebrafish embryos were injected at the 1–2-cell stage with morpholinos designed to mimic 
ColVIa exon 9 splicing defects common in UCMD.[47] Control morpholinos represent 
sequences not found in the zebrafish genome. Exon 9 morphant-treated embryos were then 
assayed using validated motor assays for defective motor function and muscle defects at 24 
and 48 h post-fertilization (hpf). Motor function was assessed by spontaneous coiling events, 
reflecting twisted myofibrils, and “touch-evoked escape response”.[45a] This assay measures 
the ability of embryos to “escape” after touching them with a small tip. The responses of 
embryos in this assay were subdivided into four groups according to their ability to escape: 
normal embryos with unaltered ability to swim, embryos with minor motility disruptions, 
embryos showing only spontaneous coiling events around the body axis without the ability 
to escape, and paralyzed embryos with no motility. As reflected in Figure 7A,B, 87% of 
embryos injected with exon 9 morpholino showed severe motor impairments relative to 
control embryos. In contrast, exon 9 morphants treated with 60, simply added to the fish 
water, showed a dramatic improvement in motor function as demonstrated with spontaneous 
coiling events (Figure 7A) or touch-evoked response (Figure 7B).
To assess structural muscle organization, muscle birefringence was evaluated at 48 hpf. This 
technique evaluates muscle structural defects in zebrafish models of muscular dystrophy.[48] 
Muscle birefringence was analyzed by taking advantage of muscle fiber anisotropy. As can 
be seen in Figure 7C, exon 9 morphants exhibited severe muscle defects relative to controls, 
and these defects were largely ameliorated following treatment with 60. Indeed, total 
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birefringence scores demonstrated that treatment with 60 generated significant recovery of 
muscle defects (ANOVA, p < 0.05).
Conclusions
In summary, a high-throughput screening and SAR optimization effort to identify mtPTP 
inhibitors has resulted in isoxazole compounds whose structure, activity, and properties were 
optimized to yield highly valuable probes with picomolar inhibitory activity and potential 
for further development as treatments for a variety mtPTP-related diseases. We confirmed 
that the isoxazole inhibitors do not interfere with the IMM potential and are protective 
against known chemical activators of the mtPTP that induce oxidative stress and trigger pore 
opening. Moreover, the key analogues demonstrated activity synergistic with CsA, 
suggesting that the target is not CyPD. We noted that the isoxazole inhibitors do not affect 
the inherent function of F-ATP synthase or impact the cell viability at effective 
concentrations. Detailed studies to identify the biological mechanism of action for these 
compounds are underway. Finally, we validated the therapeutic potential and in vivo 
efficacy of the most efficacious analogue, 60, in the zebrafish ColVI myopathic model. 
Future lead optimization work will focus on improving the in vitro and in vivo 
pharmacokinetic properties for the compound series and on evaluating the resulting 
analogues for activity in a variety of mtPTP-related disease models.
Experimental Section
Chemistry
General procedures—All solvents and reagents were used as received from commercial 
suppliers, unless noted otherwise. 1H and 13C NMR spectra were recorded on a Bruker AM 
400 spectrometer (operating at 400 and 101 MHz, respectively) or a Bruker AVIII 
spectrometer (operating at 500 and 126 MHz, respectively) in CDCl3 with 0.03% TMS as an 
internal standard. Chemical shifts (δ) are reported in parts per million (ppm), and coupling 
constants (J) are in Hertz (Hz). Spin multiplicities are reported as s=singlet, d=doublet, 
t=triplet, q=quartet, dd=doublet of doublet, ddd=doublet of doublet of doublet, dt=doublet of 
triplet, td=triplet of doublet, and m=multiplet. Microwave reactions were carried out using a 
Biotage Initiator Classic. Column chromatography separations were performed using the 
Teledyne Isco CombiFlash Rf using RediSep Rf silica gel columns. Analytical RPLC 
involved an Agilent 1200 RRLC system with UV detection (Agilent 1200 DADSL) and 
mass detection (Agilent 6224 TOF). Analytical method conditions included a Waters Aquity 
BEH C18 column (2.1×50 mm, 1.7 µm) and elution with a linear gradient of 5% CH3CN in 
buffered aqueous ammonium formate (pH 9.8) to 100% CH3CN at a flow rate of 0.4 mL 
min−1. Automated preparative RP HPLC purification was performed using an Agilent 1200 
Mass-Directed Fractionation system (Prep Pump G1361 with gradient extension, make-up 
pump G1311A, pH modification pump G1311A, HTS PAL autosampler, UVDAD detection 
G1315D, fraction collector G1364B, and Agilent 6120 quadrupole spectrometer G6120A). 
Preparative chromatography conditions included a Waters X-Bridge C18 column (19×150 
mm, 5 µm, with 19×10 mm guard column), elution with a H2O/CH3CN gradient, which 
increased to 20% CH3CN content over 4 min at a flow rate of 20 mL min−1 (modified to pH 
9.8 by the addition of NH4OH by auxiliary pump), and sample dilution in DMSO. The 
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preparative gradient, triggering thresholds, and UV wavelength were selected according to 
the analytical RP HPLC analysis of each crude sample. Compound purity was measured on 
the basis of peak integration (area under the curve) from UV/Vis absorbance at λ 214 nm, 
and compound identity was determined on the basis of mass spectral and NMR analyses. All 
compounds had >95% purity as determined by the HPLC methods described above.
General synthesis procedure—To a solution of isoxazole carboxylic acid (0.390 
mmol, 1 equiv) in dry THF (1.5 mL) in a 4-dram vial was added SOCl2 (0.558 mmol, 1.43 
equiv), and the resulting solution was stirred at reflux for 0.5 h. After cooling the reaction 
mixture to 35°C, a solution of 5-chloro-2-methylaniline (0.390 mmol, 1 equiv) and Et3N 
(1.560 mmol, 4 equiv) in dry THF (1 mL) was added dropwise. After stirring at RT for 2 h 
the reaction mixture was quenched by the addition of 1 N HCl and extracted with EtOAc 
(3×2 mL). The combined organic layer was dried over anhydrous Na2SO4, filtered, and 
concentrated. The residue was analyzed and purified according to the analytical- and 
preparative-scale RP HPLC methods.
N-(5-Chloro-2-methylphenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-
carboxamide (46)—This compound was prepared following the general procedure using 
5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (11 mg, 0.047 mmol) and 5-
chloro-2-methylaniline (7 mg, 0.047 mmol). Isolated compound 46 as an off-white powder 
(8 mg, 47 %): mp: 186–192°C (dec.); 1H NMR (400 MHz, [D6]DMSO): δ=10.28 (s, 1H), 
9.49 (s, 1H), 7.52 (d, J=2.2 Hz, 1H), 7.41 (dd, J=8.4, 2.2 Hz, 1H), 7.36–7.29 (m, 2H), 7.30–
7.22 (m, 2H), 7.09 (d, J=8.5 Hz, 1H), 3.85 (s, 3H), 2.24 ppm (s, 3H); 13C NMR (101 MHz, 
[D6]DMSO): δ=170.9, 159.2, 157.4, 150.0, 146.9, 136.5, 132.1, 131.8, 129.8, 126.0, 125.5, 
117.8, 112.5, 98.4, 55.7, 17.2 ppm; HRMS (ESI TOF) m/z: [M+H]+ calcd for 
C18H16ClN2O4: 359.0793, found: 359.0789.
N-(5-Chloro-2-methylpyridin-3-yl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-
carboxamide (54)—This compound was prepared following the general procedure using 
5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106 mmol) and 5-
chloro-2-methylpyridin-3-amine (15 mg, 0.106 mmol). Isolated compound 54 as an off-
white powder (9 mg, 23%): mp: 216–222 °C (dec.); 1H NMR (500 MHz, [D6]DMSO): 
δ=10.56 (s, 1H), 9.50 (bs, 1H), 8.44 (d, J=2.3 Hz, 1H), 8.00 (d, J=2.3 Hz, 1H), 7.42 (dd, 
J=8.4, 2.2 Hz, 1H), 7.34 (d, J=2.2 Hz, 1H), 7.29 (s, 1H), 7.10 (d, J=8.5 Hz, 1H), 3.85 (s, 
3H), 2.45 ppm (s, 3H); 13C NMR (126 MHz, [D6]DMSO): δ=171.1, 159.1, 157.8, 152.4, 
150.1, 146.9, 144.8, 133.1, 132.2, 127.8, 118.9, 117.9, 112.5, 98.5, 55.7, 20.6 ppm; HRMS 
(ESI TOF) m/z: [M+H]+ calcd for C17H15ClN3O4: 360.0746, found: 360.0816.
N-(3-Chloro-2-methylphenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-
carboxamide (60)—This compound was prepared following the general procedure using 
5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (29 mg, 0.130 mmol) and 3-
chloro-2-methylaniline (18 mg, 0.130 mmol). Isolated compound 60 as an off-white powder 
(14 mg, 30%): mp: 242–246°C (dec.); 1H NMR (500 MHz, [D6]DMSO): δ=10.56 (s, 1H), 
10.41 (s, 1H), 7.50 (dd, J=8.3, 2.2 Hz, 1H), 7.47–7.38 (m, 3H), 7.39–7.31 (m, 2H), 7.28 (t, 
J=8.0 Hz, 1H), 2.26 ppm (s, 3H); 13C NMR (126 MHz, [D6]DMSO): δ=169.9, 158.5 (d, 
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J=247.1 Hz), 153.5, 151.6, 145.6 (d, J=12.8 Hz), 136.7, 133.8, 132.1, 127.3, 127.0, 125.9, 
123.0 (d, J=3.4 Hz), 117.8 (d, J=7.2 Hz), 117.3 (d, J=19.2 Hz), 114.9 (d, J=3.6 Hz), 99.9, 
15.3 ppm; HRMS (ESI TOF) m/z: [M+H]+ calcd for C17H13ClFN2O3: 347.0593, found: 
347.0597.
N-(5-Chloro-2-methylphenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-
carboxamide (63)—This compound was prepared following the general procedure 
(isoxazole amide) 1 using 5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 
0.112 mmol) and 5-chloro-2-methylaniline (16 mg, 0.112 mmol). Isolated compound 63 as 
an off-white powder (7 mg, 18%): mp: 214–216 °C (dec.); 1H NMR (500 MHz, 
[D6]DMSO): δ=10.36 (s, 1H), 7.51 (dd, J=7.0, 2.1 Hz, 2H), 7.43 (ddd, J=8.4, 4.3, 2.2 Hz, 
1H), 7.40 (s, 1H), 7.39–7.30 (m, 2H), 7.27 (dd, J=8.2, 2.3 Hz, 1H), 2.24 ppm (s, 3H); 13C 
NMR (126 MHz, [D6]DMSO): δ=169.9, 159.4, 157.3, 152.6 (d, J=246.5 Hz), 145.8 (d, 
J=12.8 Hz), 136.4, 132.3, 131.9, 129.8, 126.1, 125.6, 117.5 (d, J=7.0 Hz), 117.2 (d, J=19.3 
Hz), 114.9 (d, J=3.8 Hz), 99.8, 17.2 ppm; HRMS (ESI TOF) m/z: [M+H]+ calcd for 
C17H13ClFN2O3: 347.0593, found: 347.0599.
Biology
Reagents—Sucrose, 3-(N-morpholino) propanesulfonic acid (MOPS), phosphoric acid, 
tris(hydroxymethyl)aminomethane (Tris), ethylene glycol tetraacetic acid (EGTA), glutamic 
acid, malic acid, CsA, phenylarsine oxide (PhAsO), diamide, N-ethylmaleimide (NEM), 
bovine serum albumin (BSA), CaCl2, carbonylcyanide-p-trifluoromethoxyphenyl hydrazone 
(FCCP), verapamil, and dimethyl sulfoxide (DMSO) were from Sigma–Aldrich, CsH was 
from Enzo Life Sciences, digitonin was from Calbiochem, Rh123 and Calcium Green-5N 
were from Invitrogen, copper-o-phenanthroline (Cu(OP)2) was prepared just before use by 
mixing CuSO4 with o-phenanthroline at a 1:2 molar ratio in double-distilled water. All 
chemicals were of the highest purity commercially available; 96-well plates were from 
Sacco S.r.l., Italy.
Animal studies—All procedures were approved by the CEASA of the University of 
Padova (72/2012 and 39/214 to P.B.) and authorized by the Italian Ministry of Health.
General methodology—Assays on biological samples, including purified mitochondria, 
cultured cells, and zebrafish were treated with compounds described in this study at a final 
DMSO concentration of 1%. The compound concentrations stated in biological experiments 
refer to the “formal” concentration, that is, moles added/volume, making no assumption as 
to the influence of biological materials on the concentration of added compound.
Isolation of mitochondria—C57BL6/J mouse liver mitochondria were prepared from 
mice aged between 3 and 6 months by standard differential centrifugation. Mice fed ad 
libitum were sacrificed by cervical dislocation, their livers were removed and placed in a 
glass beaker containing ice-cold isolation buffer (IB: 0.25M sucrose, 10 mM Tris·HCl, 0.1 mM 
EGTA-Tris, pH 7.4) supplemented with BSA. Livers were then cut into small pieces with 
scissors, rinsed with ice-cold IB, and passed through a pre-chilled Potter homogenizer with 
Teflon pestle. The homogenate (~30 mL per liver) was transferred to centrifuge tubes, and 
Roy et al. Page 12













unbroken cells and nuclei were removed by centrifugation at 685×g for 10 min at 4 °C. The 
supernatant containing mitochondria and other organelles was transferred to new tubes and 
centrifuged at 6010×g for 10 min at 4 °C. The resulting supernatant was discarded, and 
mitochondrial pellet was carefully suspended in ice-cold IB buffer and spun at 9390×g for 5 
min at 4°C. The pellet was suspended in IB to give a protein concentration of ~60–80 mg 
mL−1 and stored on ice. Experiments were started immediately and completed within 5 h. 
Protein concentration was determined by the Biuret method.[49]
Cell culture—HeLa cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (Invitrogen), 100 U mL−1 penicillin and 100 µg 
mL−1 streptomycin (Invitrogen) in a humidified atmosphere of 5% CO2/95% air at 37°C.
Assessment of mitochondrial swelling—Changes in mitochondrial volume of 
isolated mouse liver mitochondria were followed in a 96-well clear assay plate (Falcon 
353072) at a final volume of 0.2 mL. First, 0.1 mL of sucrose assay buffer (SAB: 250 mM 
sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mM phosphoric acid-Tris, 10 mM 
glutamate, and 5 mM malate, pH 7.4) supplemented with twice the Ca2+ concentration 
required to induce mitochondrial swelling (which was determined for each preparation of 
mitochondria, typically 50 µM) was dispensed to the assay plate. A set of wells also 
contained 2.0 mM EGTA (to prevent mitochondrial swelling). The test wells contained a 
range of concentrations of the compounds of interest or 2% DMSO. Experiments were 
started by the addition of 0.1 mL of mitochondrial suspension (0.5 mg mL−1 mitochondria in 
SAB without respiratory substrates) to the assay plates. Absorbance was read for 30 min at λ 
540 nm with a Multi-Skan EX (Thermo Scientific) plate reader.
Assessment of mitochondrial membrane potential—Mitochondrial membrane 
potential of isolated mouse liver mitochondria was assessed based on accumulation of the 
cationic fluorescent dye Rh123. First, 0.1 mL of SAB was dispensed to a 96-well black 
assay plate (Falcon 353376). A set of wells also contained 0.8 µM FCCP (to prevent Rh123 
uptake). The test wells contained a range of concentrations of the compounds of interest or 
2% DMSO. Then, 0.1 mL of 0.5 mg mL−1 mitochondria in SAB devoid of respiratory 
substrates and supplemented with 0.8 µM Rh123 were added to all wells of the assay plate. 
Following incubation at room temperature for 5 min, fluorescence intensity (λex 485 nm, 
λem 538 nm) was read on a Fluoroskan Ascent FL (Thermo Scientific) plate reader.
Assessment of calcium retention capacity—Calcium retention capacity (CRC) of 
isolated mouse liver mitochondria was assessed as follows: First, 0.1 mL of SAB were 
dispensed to a 96-well black assay plate (Falcon 353376) in the presence of 2% DMSO 
(control wells) or varying concentrations of test compounds. Then, 0.1 mL of 0.5 mg mL−1 
mitochondria in SAB devoid of respiratory substrates but supplemented with 1 µM Calcium 
Green-5N were added to all wells of the assay plate. A train of 5, 10, or 20 µM Ca2+ pulses 
was added at 1.5, 3, or 4.5 min intervals, respectively, and fluorescence intensity (λex 485 
nm, λem 538 nm) was read on Fluoroskan Ascent FL (Thermo Scientific) plate reader.
CRC of HeLa cells—The cells were cultured for 48 h to reach 70–80% confluency, then 
harvested by trypsinization and washed in KCl buffer (KB: 130 mM KCl, 10 MOPS-Tris, 1 
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mM phosphoric acid-Tris, 0.1 mM EGTA-Tris, pH 7.4). Cells were then suspended in the 
above buffer to 8×106 cells per mL and treated with 1.56 µM 60 or DMSO on ice for 30 min, 
followed by excess compound elimination by centrifugation (experiments presented in 
Figure 4E only; the step was omitted in experiments of Figure 4F). The pellet was 
resuspended in KB (except that EGTA-Tris was increased to 1.0 mM) to give a concentration 
of 2×107 cells per mL and treated with 0.1 mM digitonin for 10 min on ice to permeabilize 
the plasma membrane. Following excess digitonin elimination by washing cells twice in KB, 
the cells were suspended to 8×106 cells per mL in KB containing 10 µM EGTA-Tris and 
supplemented with 1 µM Calcium Green-5N and processed as described for isolated mouse 
liver mitochondria.
Measurement of respiration—Mitochondrial oxygen consumption was assessed with 
the Seahorse Extracellular Flux Analyzer XF24 (Seahorse Bioscience, Billerica, MA, USA) 
essentially as described previously.[50] Briefly, mitochondrial assay solution contained 220 
mM mannitol, 70 mM sucrose, 25 mM MOPS-Tris, 10 mM Pi-Tris, 5 mM MgCl2, 1 mM EGTA-
Tris, 0.2% fatty-acid-free BSA, 5 mM succinate, and 2 µM rotenone, pH 7.4. Mitochondria (5 
µg, suspended in 50 µL mitochondrial assay solution) were added to each well of an XF24 
cell culture microplate, centrifuged at 2000×g for 20 min at 4 °C, and then supplemented 
with 450 µL of mitochondrial assay solution containing 4 mM ADP to initiate the 
experiments. Additions were as indicated in Figure 6A. Cellular oxygen consumption was 
assessed with the Seahorse Extracellular Flux Analyzer XF24[51] on monolayers of HeLa 
cells seeded at a density of 3×104 per well in 0.2 mL DMEM and cultured for 24 h. Assays 
were started by replacing the growth medium with 0.5 mL serum and antibiotic-free 
unbuffered DMEM (pH 7.4) supplemented with the multidrug resistance inhibitor verapamil 
(20 µM, data not shown) or CsH (2 µg mL−1), and additions were made as indicated in Figure 
6C. At the end of the experiment the protein content per well was quantified with a BCA 
Protein Assay Kit (Thermo Scientific-Pierce).
Cell viability assay—HeLa cells were seeded at a density of 1×104 per well in 96-well 
plates and let to adhere for 6 h before treatment with varying concentrations of 60 or vehicle 
(1% DMSO) in the presence of the multidrug resistance inhibitor verapamil (20 µM) or CsH 
(2 µg mL−1). After treatment for 24 h the relative viable cell number was determined with a 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit (Promega).
Zebrafish and embryo maintenance—Adult zebrafish were maintained in the facility 
of the University of Padova containing aerated, 28.5 °C-conditioned saline water according 
to standard protocols. Fish were kept under a 14 h light–10 h dark cycle. For mating, males 
and females were separated in the late afternoon, and were freed to start courtship the next 
morning, which ended with egg deposition and fecundation. Eggs were collected, washed 
with fish water (0.5 mM NaH2PO4, 0.5 mM NaHPO4, 0.2 mg L−1 methylene blue, 3 mg L−1 
instant ocean) and embryos were maintained at 28.5 °C. All protocols and manipulations 
with zebrafish were performed as described.[52]
Morpholino injections—To reproduce the dominant negative UCMD or BM phenotype 
in zebrafish, we used a previous published exon 9 morpholino,[28] which targets exon 9 of 
Roy et al. Page 14













the zebrafish col6a1 gene. Exon 9, col6a1: GAG AGC GGA AGA CGA ACC TTC ATTC 
(GeneTools, Inc.). A control morpholino, with no sequence homology in zebrafish genome 
was used. Embryos isolated after paired matings of wild-type zebrafish were injected at 1–2 
cell stage using a WPI pneumatic PicoPump PV820 injector. Morpholino was injected at a 
concentration of 0.1 mM, corresponding to ~4 ng per embryo.
Compound treatment—Morphant embryos were dechorionated at 20 hpf and then 
treated with 60 at 21 hpf. Untreated morphants and wild-type embryos were used as 
controls. Compound 60 was used at 5 and 10 µM and dissolved in fish water with 1% DMSO. 
Vehicle control treatment consisted of fish water with 1% DMSO. Analyses of compound 
effects on embryos were performed as described at 24 and 48 hpf.
Motor activity—Spontaneous coiling rates were recorded by observing the number of 
coiling events in 15 s for single embryos at 24 hpf using light microscopy. Touch-evoked 
escape response was measured at 48 hpf by observing the ability of larvae to escape after 
touching the body with a little tip. Embryos were subdivided into four groups according to 
their ability to escape: paralyzed with no ability to move, showing coiling events only, 
embryos with minor motor impairments, or normal embryos swimming in the fish water; 
these were assigned a score of 0, 1, 2, or 3, respectively. Statistical analysis was performed 
on mean scores at each experimental condition.
Birefringence assay—Muscle birefringence was measured at 48 hpf on tricaine-
anesthetized embryos by taking advantage of muscle fiber anisotropy. It was measured using 
two polarizing filters on a Leica M165FC stereomicroscope. Briefly, anesthetized embryos 
were placed on a glass slide, and muscle light refraction was analyzed by using two 
polarizing filters. The first filter produces the polarized light to illuminate the sample, and 
the second polarizing filter, called the analyzer, calculates the angle of light refracted from 
muscle fibers. In particular, the top polarizing filter was twisted at a 90° angle until the light 
refracting through the muscle was visible through a stereomicroscope. Integrated area of 
birefringence was calculated by using ImageJ software.[48] Birefringence values ≥2×106 
(typical of wild-type individuals) were rated as normal, values between 1.9 and 0.6×106 
were considered as an indication of mild disease, and values ≤ 0.6×106 were rated as an 
indication of severe myopathy. Statistical analysis was performed on the mean birefringence 
values at each experimental condition.
Statistical analysis—Differences between control and compound-treated samples were 
determined by one-way ANOVA test with Bonferroni correction using GraphPad Prism 
(version 5.1 for Windows). Data represent the mean of at least five independent experiments 
(n=52 for each condition) ± SEM; **p < 0.01, ***p < 0.001 for Figure 7A. For Figure 7B, 
comparison between groups at different conditions was made using χ2 test and one-way 
ANOVA with Bonferroni correction; **p < 0.01, ***p < 0.001. For Figure 7B,C, the total 
number of embryos used is n=35 for each condition; *p < 0.05, ***p < 0.001, as determined 
by χ2 test and one-way ANOVA with Bonferroni correction.
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Structures of prominent mtPTP inhibitors.
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Regions of hit 1 earmarked for optimization.
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SAR overview. CRC ratios at 1.56 µM compound concentration (bars), swelling (circles), and 
Rh123 uptake (squares). EC50 values are for isolated mouse liver mitochondria. Data are the 
average ± SEM of n ≥ 3 experiments. Values equal to those on the dashed line represent 
EC50 > 50 µM and > 100 µM for the swelling and Rh123 uptake assays, respectively.
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Effect of 60 on Ca2+-induced mtPTP. A) Mitochondrial swelling was induced with 50 µM 
Ca2+, which was prevented with 60. B) Concentration–response of experiment described in 
panel A (■) and interference with Rh123 uptake (□). C) Representative CRC of DMSO-, 
CsA-, 60-, and CsA + 60-treated mitochondria; D) Concentration–response of 60 (■) and 
CsA (2 µM) + 60 (□)-to-solvent CRC ratios; assays were performed on isolated mouse liver 
mitochondria (0.25 mg mL−1). E) Representative CRCs of HeLa cells treated with DMSO 
(trace a) or 60 (1.56 µM; trace c) before cell permeabilization with digitonin; trace b: cells 
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were treated as in trace a and CRC was performed in the presence of 60 (1.56 µM). F) 60-to-
solvent CRC ratios of permeabilized HeLa cells (0.8×106 per condition). Data are the 
average ± SEM of n ≥ 5 experiments.
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Effect of 60 on chemical activation of the mtPTP. Suspension of isolated mouse liver 
mitochondria (0.25 mg mL−1) were supplemented with 10 µM Ca2+ only (traces a); 10 µM 
Ca2+ and A) 7 µM PhAsO, B) 2 mM diamide, C) 7 µM Cu(OP)2, or D) 2 mM NEM (traces b–d). 
In traces c and d, 1.56 µM CsA or 60, respectively, were also present. Traces are 
representative of four separate experiments.
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Effect of 60 on oxygen consumption rate (OCR) and HeLa cell proliferation. A) OCR of 
ADP + Pi-stimulated isolated mouse liver mitochondria. B) Ratios of OCR before-to-after 
addition of oligomycin. C) OCR of HeLa cells. D) Interference with HeLa cell proliferation 
after 24 h treatment with the indicated concentration of compound 60. In panels C and D, 
the multidrug resistance inhibitor CsH (2 µg mL−1) was also present. Similar results were 
obtained with 20 µM verapamil. A), C) Data are the average ± SD of a representative 
experiment performed four separate times. B), D) Data are the average ± SEM of four and 
five experiments, respectively; ***p < 0.001 as assessed by t-test.
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Effect of 60 on defects present in exon 9 col6a1 morphant zebrafish. A) Coiling events were 
recorded at 24 hpf in control (CRL_MO) and exon 9 morphant (Ex9_MO) embryos in the 
presence of the indicated concentrations of 60 added at 21 hpf. Data are the mean ± SEM of 
at least five independent experiments (n = 52 for each condition); **p < 0.01, ***p < 0.001 
as determined by one-way ANOVA test with Bonferroni correction. B) In the presence of 
the indicated concentrations of 60 added at 21 hpf, response evoked by touching embryos at 
24 hpf with a pipette tip were recorded. Embryos (n = 35 for each condition) were assigned 
to four groups based on their escape response: normal, low motility defects, spontaneous 
coiling events only, and complete paralysis. Results are reported as the percentage of total 
embryos analyzed for each group. Comparison between groups at different conditions was 
made using χ2 test and one-way ANOVA with Bonferroni correction; **p < 0.01, ***p < 
0.001. C) Bar graphs report the percentage of birefringence classes at 48 hpf after treatment 
with compound 60 added at 21 hpf, showing normal birefringence, mild myopathic 
phenotype, and strong myopathic phenotype, as indicated. The total number of embryos 
used was n = 35 for each condition; *p < 0.05, ***p < 0.001, as determined by χ2 test and 
one-way ANOVA with Bonferroni correction.
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Synthetic route for the assembly of isoxazole analogues. Reagents and conditions: a) SOCl2, 
Et3N, 65°C→RT, THF, 20–80%.
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Synthetic route for isoxazole carboxylic acid intermediates. Reagents and conditions: a) 
dimethyl oxalate, NaOMe, Et2O, RT, 24 h, 60–80 %; b) NH2OH·HCl/NH2-NH2·H2O/
MeNH-NH2, MeOH/AcOH, reflux, 1/18 h, 40–90%; c) NaOH, EtOH/THF (2:1), reflux, 2 h, 
70–98%.
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Table 2
Structure–activity relationships around the eastern aryl ring.
Entry Structure CRC/CRC0[a,b] EC50 [µm][a]
Mito[c] Rh123[d]
34 1.00±0.00 >50 >100
35 1.00±0.00 >50 >100
36 1.00±0.00 >50 >100
37 1.03±0.08 44.6±3.0 >100
38 1.00±0.00 >50 >100
39 2.10±0.20 2.21±0.17 >100
40 1.46±0.15 2.45±0.15 >100
41 1.24±0.09 >50 >100
42 1.00±0.00 >50 >100
43 1.25±0.09 6.05±0.75 >100
44 0.98±0.02 >50 >100
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Entry Structure CRC/CRC0[a,b] EC50 [µm][a]
Mito[c] Rh123[d]
45 1.02±0.02 >50 >100
[a]
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Table 6
Summary of in vitro ADME data for compound 60.
Parameter[a] Compd 60
Aqueous solubility [µM] (PBS, pH 7.4) 16.1
Protein binding {recovery} [%] (human; mouse) 89 {76}; > 99 {0}
Plasma stability t1/2 [min] (human; mouse)[b] > 120; < 30
CLint HLM [µL min−1 mg−1][b,c]; t1/2 [min][b] <115.5; >60
CLint MLM [µL min−1 mg−1][b,d]; t1/2 [min][b] > 462; < 15
[a]
Data collected at Cerep/Eurofins Panlabs.
[b]
The remaining compound percentage at multiple time points is reported in the Supporting Information.
[c]
Intrinsic clearance, human liver microsomes.
[d]
Intrinsic clearance, mouse liver microsomes.
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